Back to Search Start Over

WWOX binds MERIT40 and modulates its function in homologous recombination, implications in breast cancer.

Authors :
Taouis K
Vacher S
Guirouilh-Barbat J
Camonis J
Formstecher E
Popova T
Hamy AS
Petitalot A
Lidereau R
Caputo SM
Zinn-Justin S
Bièche I
Driouch K
Lallemand F
Source :
Cancer gene therapy [Cancer Gene Ther] 2023 Aug; Vol. 30 (8), pp. 1144-1155. Date of Electronic Publication: 2023 May 29.
Publication Year :
2023

Abstract

The tumor suppressor gene WWOX is localized in an unstable chromosomal region and its expression is decreased or absent in several types of cancer. A low expression of WWOX is associated with a poor prognosis in breast cancer (BC). It has recently been shown that WWOX contributes to genome stability through its role in the DNA damage response (DDR). In breast cancer cells, WWOX inhibits homologous recombination (HR), and thus promotes the repair of DNA double-stranded breaks (DSBs) by non-homologous end joining (NHEJ). The fine-tuning modulation of HR activity is crucial. Its under or overstimulation inducing genome alterations that can induce cancer. MERIT40 is a positive regulator of the DDR. This protein is indispensable for the function of the multi-protein complex BRCA1-A, which suppresses excessive HR activity. MERIT40 also recruits Tankyrase, a positive regulator of HR, to the DSBs to stimulate DNA repair. Here, we identified MERIT40 as a new molecular partner of WWOX. We demonstrated that WWOX inhibited excessive HR activity induced by overexpression of MERIT40. We showed that WWOX impaired the MERIT40-Tankyrase interaction preventing the role of the complex on DSBs. Furthermore, we found that MERIT40 is overexpressed in BC and that this overexpression is associated to a poor prognosis. These results strongly suggest that WWOX, through its interaction with MERIT40, prevents the deleterious impact of excessive HR on BC development by inhibiting MERIT40-Tankyrase association. This inhibitory effect of WWOX would oppose MERIT40-dependent BC development.<br /> (© 2023. The Author(s).)

Details

Language :
English
ISSN :
1476-5500
Volume :
30
Issue :
8
Database :
MEDLINE
Journal :
Cancer gene therapy
Publication Type :
Academic Journal
Accession number :
37248434
Full Text :
https://doi.org/10.1038/s41417-023-00626-x